Sorrento Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sorrento Therapeutics, Inc.
The biotech announced promising Phase IIa results for abivertinib in marginal zone lymphoma and is in talks with Chinese regulators about a Phase III trial.
Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair. Use of decentralized mode for its Phase III trials is a notable aspect.
Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
- Medical Devices
- Specialty Pharmaceuticals
- Site Specific
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Large Molecule
- Other Names / Subsidiaries
- ADNAB, Inc.
- Levena (Suzhou) Biopharma Co., Ltd
- SCILEX Pharmaceuticals, Inc.
- Scilex Holding Company
- Scintilla Pharmaceuticals, Inc.
- Semnur Pharmaceuticals, Inc.
- Sherrington Pharmaceuticals
- SmartPharm Therapeutics, Inc.
- TNK Therapeutics, Inc.
- Virttu Biologics Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.